Literature DB >> 1542301

Activation of the fifth component of human complement, C5, without cleavage, by methionine oxidizing agents.

W Vogt1, B Zimmermann, D Hesse, R Nolte.   

Abstract

Purified human C5 was incubated with chloramine T (Cl-T) or N-chloro-succinimide (N-Cl-S) in barbital buffer, pH 7.2. The treatment led to C5 activation: Cl-T- and N-Cl-S-treated C5 acquired a binding site for C6; upon incubation with C6 and subsequent addition of C7, C8 and C9 a membrane attack complex formed which lysed non-sensitized guinea pig red cells (reactive lysis). While the physiological activation of C5 follows its specific cleavage, the resulting fragment C5b representing the activated C5 and expressing the C6 binding site, the treatment with the mentioned chemicals does not lead to fragmentation of the C5 protein. So, functionally, the product of the chemical treatment is C5b-like, but chemically, it comprises the whole protein; no C5a is released. Cl-T and N-Cl-S are known to more or less selectively oxidize methionine residues in proteins, dependent on the conditions. Other sensitive amino acid residues are tryptophan and cysteine. Conditions were chosen for treatment of C5 with Cl-T which exclude attack on tryptophan, and we have ensured that human C5 does not contain free cysteine residues. Further, oxidation of about 60% of the methionine residues of C5 by Cl-T was demonstrated by amino acid analysis. So, all evidence points to methionine residue(s) as the site of attack of Cl-T and probably also of N-Cl-S. The oxidation product of methionine, its sulphoxide, may cause a change in structural conformation of C5 which involves expression of the C6 binding site. Earlier it was found that oxidation of C5 by hydroxyl radicals leads to its activation without cleavage. Since the properties of this C5b-like product resemble those of the product of treatment with Cl-T and N-Cl-S, it is suggested that the formerly found activation of human C5 by hydroxyl radicals is also mediated by oxidation of methionine residue(s) in the C5 protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1542301     DOI: 10.1016/0161-5890(92)90106-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement.

Authors:  B J Czermak; A B Lentsch; N M Bless; H Schmal; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

2.  Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor.

Authors:  K S Kilgore; P A Ward; J S Warren
Journal:  Inflammation       Date:  1998-12       Impact factor: 4.092

3.  Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

Authors:  Elena B Volokhina; Grethe Bergseth; Nicole C A J van de Kar; Lambertus P van den Heuvel; Tom Eirik Mollnes
Journal:  Blood       Date:  2015-07-09       Impact factor: 22.113

4.  Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation.

Authors:  K S Kilgore; E Schmid; T P Shanley; C M Flory; V Maheswari; N L Tramontini; H Cohen; P A Ward; H P Friedl; J S Warren
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

5.  The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils.

Authors:  Enrico Lupia; Lorenzo Del Sorbo; Serena Bergerone; Giorgio Emanuelli; Giovanni Camussi; Giuseppe Montrucchio
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

6.  The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells.

Authors:  K S Kilgore; C M Flory; B F Miller; V M Evans; J S Warren
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

Review 7.  Complement in Kidney Transplantation.

Authors:  Marek Cernoch; Ondrej Viklicky
Journal:  Front Med (Lausanne)       Date:  2017-05-30

8.  C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.

Authors:  Elena Panayiotou; Eleni Fella; Revekka Papacharalambous; Stavros Malas; Maria Joao Saraiva; Theodoros Kyriakides
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.